← Back

Zhejiang DiAn Diagnostics Co

Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated pathology slide staining system, genotyping DNA test kit, human papillomavirus nucleic acid detection kit, PCR system and detection system, and virus collection and preservation system; and multi-omics platform services. It also provides DP-TOF nucleic acid mass spectrometry solutions, including mass spectroscopy system, automatic sample processing system, respiratory pathogens multiple detection kit, and nucleic acid sample pretreatment reagent kit; and forensic drug testing products comprises diangio, hair drug trace tester and detector, and saliva and urine drug testing product series. In addition, the company offers diagnostic product supply, medical testing services, supply chain optimization, digital operation management, laboratory quality system construction, and professional cold chain logistics services. Further, it is involved in the research and development of diagnostic products; and vitro diagnostic reagents, as well as forensic identification, health management, and other fields. The company was formerly known as Zhejiang DIAN Diagnostics Co., Ltd. and changed its name to Dian Diagnostics Group Co.,Ltd. in November 2017. Dian Diagnostics Group Co.,Ltd. was founded in 1996 and is based in Hangzhou, China.

Price · split & dividend adjusted
News & notes moving 300244.CS
300244.CS4

Dian Diagnostics' 2026 interim report shows net profit of 232 million yuan, up 2160.87% year-on-year

Dian Diagnostics released its 2026 interim report, with net profit attributable to the parent company of 232 million yuan, up 2160.87% from the same period last year. Total operating revenue was 4.773 billion yuan, down 3.30% year-on-year. Net cash inflow from operating activities was 259 million yuan, down 6.59% year-on-year. The latest asset-liability ratio was 37.97%, down 5.04 percentage points from the same period last year. Gross margin was 30.12%, rising for two consecutive quarters. Diluted earnings per share were 0.38 yuan, up 2163.10% year-on-year.
Jiemian·5dRead more ▾
300244.CS

Tuojing Technology's first-half net profit surges 1324.1%

Tuojing Technology achieved operating revenue of 2.913 billion yuan in the first half of 2026, up 49.06% year on year, with net profit attributable to shareholders of the listed company at 1.343 billion yuan, a surge of 1324.1%. The company also plans to distribute a cash dividend of 3.5 yuan for every 10 shares to all shareholders. Dian Diagnostics posted first-half net profit of 232 million yuan, up 2160.87% year on year; Rike Chemical's net profit was 30.27 million yuan, up 2518.58%. Ping An Insurance achieved net profit attributable to shareholders of the parent company of 92.585 billion yuan in the first half, up 36.1% year on year. Jiangsu Expressway plans to acquire a 100% stake in Suzhou-Wuxi-Changzhou Southern Expressway Company for 7.341 billion yuan in cash. Shenzhen Keda said its storage equipment business made a breakthrough, securing new orders of about 57.926 million yuan from a well-known North American HDD storage manufacturer in the first half.
上海证券报·6dRead more ▾